Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease

Pharmacological Research

Volumn 76, Issue , 2013, Pages 1-8

  Coskun, Mehmet ^a   Salem, Mohammad ^a   Pedersen, Jannie ^a   Nielsen, Ole Haagen ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Crohn's disease; Inflammatory bowel disease; Janus kinase; Tofacitinib; Ulcerative colitis

Indexed keywords

GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PROTEIN KINASE TYK2; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; BONE MARROW CELL; CD4 LYMPHOCYTE COUNT; CELL ACTIVITY; CROHN DISEASE; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFECTION; INTESTINE EPITHELIUM CELL; INTRACELLULAR SIGNALING; LYMPHOMA; NEOPLASM; NEUTROPHIL COUNT; NONHUMAN; OUTCOME ASSESSMENT; PERIANAL ABSCESS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TH1 CELL; TH17 CELL; TH2 CELL; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

CD; CROHN'S DISEASE; DEXTRAN SODIUM SULFATE; DSS; IBD; IEC; IFN; IL; INFLAMMATORY BOWEL DISEASE; INTERFERON; INTERLEUKIN; INTESTINAL EPITHELIAL CELL; JAK; JANUS KINASE; LDL; LOW-DENSITY LIPOPROTEIN; RA; REGULATORY T; RETINOID-RELATED ORPHAN RECEPTOR; RHEUMATOID ARTHRITIS; ROR; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION; STAT; T HELPER; TH; TNF; TOFACITINIB; TREG; TUMOR NECROSIS FACTOR; TYK; TYROSINE KINASE; UC; ULCERATIVE COLITIS;

ANIMALS; HUMANS; INFLAMMATORY BOWEL DISEASES; JANUS KINASES; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84882433613     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.06.007     Document Type: Review

References (141)

1. I. Ordas, L. Eckmann, M. Talamini, D.C. Baumgart, and W.J. Sandborn Ulcerative colitis Lancet 380 2012 1606 1619
2. D.C. Baumgart, and W.J. Sandborn Crohn's disease Lancet 380 2012 1590 1605
3. A. Kaser, S. Zeissig, and R.S. Blumberg Inflammatory bowel disease Annu. Rev. Immunol. 28 2010 573 621
4. R.B. Sartor Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis Nat Clin Pract Gastroenterol Hepatol 3 2006 390 407 (Pubitemid 44018812)
5. A. Franke, D.P. McGovern, J.C. Barrett, K. Wang, G.L. Radford-Smith, and T. Ahmad Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci Nat. Genet. 42 2010 1118 1125
6. C.A. Anderson, G. Boucher, C.W. Lees, A. Franke, M. D'Amato, and K.D. Taylor Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 Nat. Genet. 43 2011 246 252
7. B. Khor, A. Gardet, and R.J. Xavier Genetics and pathogenesis of inflammatory bowel disease Nature 474 2011 307 317
8. L. Jostins, S. Ripke, R.K. Weersma, R.H. Duerr, D.P. McGovern, and K.Y. Hui Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease Nature 491 2012 119 124
9. C. Abraham, and J.H. Cho Inflammatory bowel disease N. Engl. J. Med. 361 2009 2066 2078
10. D.N. Frank, C.E. Robertson, C.M. Hamm, Z. Kpadeh, T. Zhang, and H. Chen Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases Inflamm. Bowel Dis. 17 2011 179 184
11. N.A. Nagalingam, and S.V. Lynch Role of the microbiota in inflammatory bowel diseases Inflamm. Bowel Dis. 18 2012 968 984
12. C. Manichanh, N. Borruel, F. Casellas, and F. Guarner The gut microbiota in IBD Nat Rev Gastroenterol Hepatol 9 2012 599 608
13. C. Abraham, and R. Medzhitov Interactions between the host innate immune system and microbes in inflammatory bowel disease Gastroenterology 140 2011 1729 1737
14. B. Weber, L. Saurer, and C. Mueller Intestinal macrophages: differentiation and involvement in intestinal immunopathologies Semin Immunopathol 31 2009 171 184
15. A.W. Steel, C.M. Mela, J.O. Lindsay, B.G. Gazzard, and M.R. Goodier Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment Aliment. Pharmacol. Ther. 33 2011 115 126
16. A.L. Hart, H.O. Al-Hassi, R.J. Rigby, S.J. Bell, A.V. Emmanuel, and S.C. Knight Characteristics of intestinal dendritic cells in inflammatory bowel diseases Gastroenterology 129 2005 50 65 (Pubitemid 41002042)
17. F. Sanchez-Munoz, A. Dominguez-Lopez, and J.K. Yamamoto-Furusho Role of cytokines in inflammatory bowel disease World J. Gastroenterol. 14 2008 4280 4288
18. W.S. Garrett, J.I. Gordon, and L.H. Glimcher Homeostasis and inflammation in the intestine Cell 140 2010 859 870
19. L. Vereecke, R. Beyaert, and L.G. van Enterocyte death and intestinal barrier maintenance in homeostasis and disease Trends Mol. Med. 17 2011 584 593
20. K.J. Maloy, and F. Powrie Intestinal homeostasis and its breakdown in inflammatory bowel disease Nature 474 2011 298 306
21. D.S. Aaronson, and C.M. Horvath A road map for those who don't know JAK-STAT Science 296 2002 1653 1655 (Pubitemid 34579157)
22. M. Coskun, J. Olsen, J.B. Seidelin, and O.H. Nielsen MAP kinases in inflammatory bowel disease Clin. Chim. Acta 412 2011 513 520
23. T. Kisseleva, S. Bhattacharya, J. Braunstein, and C.W. Schindler Signaling through the JAK/STAT pathway, recent advances and future challenges Gene 285 2002 1 24 (Pubitemid 34246317)
24. K. Ghoreschi, A. Laurence, and J.J. O'Shea Janus kinases in immune cell signaling Immunol. Rev. 228 2009 273 287
25. M.G. Cornejo, T.J. Boggon, and T. Mercher JAK3: a two-faced player in hematological disorders Int. J. Biochem. Cell Biol. 41 2009 2376 2379
26. M.M. Seavey, and P. Dobrzanski The many faces of Janus kinase Biochem. Pharmacol. 83 2012 1136 1145
27. J.L. Casanova, S.M. Holland, and L.D. Notarangelo Inborn errors of human JAKs and STATs Immunity 36 2012 515 528
28. C.S. Nicolas, S. Peineau, M. Amici, Z. Csaba, A. Fafouri, and C. Javalet The Jak/STAT pathway is involved in synaptic plasticity Neuron 73 2012 374 390
29. B. Gao, H. Wang, F. Lafdil, and D. Feng STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver J. Hepatol. 57 2012 430 441
30. J.J. O'Shea, and R. Plenge JAK and STAT signaling molecules in immunoregulation and immune-mediated disease Immunity 36 2012 542 550
31. G.P. Christophi, R. Rong, P.G. Holtzapple, P.T. Massa, and S.K. Landas Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease Inflamm. Bowel Dis. 18 2012 2342 2356
32. S. Danese New therapies for inflammatory bowel disease: from the bench to the bedside Gut 61 2012 918 932
33. W.J. Sandborn, S. Ghosh, J. Panes, I. Vranic, C. Su, and S. Rousell Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis N. Engl. J. Med. 367 2012 616 624
34. G.R. Stark, and J.E. Darnell Jr. The JAK-STAT pathway at twenty Immunity 36 2012 503 514
35. K. Yamaoka, P. Saharinen, M. Pesu, V.E. Holt III, O. Silvennoinen, and J.J. O'Shea The Janus kinases (Jaks) Genome Biol. 5 2004 253
36. C. Haan, P.C. Heinrich, and I. Behrmann Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation Biochem. J 361 2002 105 111 (Pubitemid 34171414)
37. S.A. Robertson, R.I. Koleva, L.S. Argetsinger, C. Carter-Su, J.A. Marto, and E.P. Feener Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling Mol. Cell. Biol. 29 2009 3367 3378
38. D.E. Levy, and J.E. Darnell Jr. Stats: transcriptional control and biological impact Nat. Rev. Mol. Cell Biol. 3 2002 651 662 (Pubitemid 34987786)
39. T. Decker, and P. Kovarik Serine phosphorylation of STATs Oncogene 19 2000 2628 2637 (Pubitemid 30339219)
40. X. Wang, P. Lupardus, S.L. Laporte, and K.C. Garcia Structural biology of shared cytokine receptors Annu. Rev. Immunol. 27 2009 29 60
41. Y. Rochman, R. Spolski, and W.J. Leonard New insights into the regulation of T cells by gamma(c) family cytokines Nat. Rev. Immunol. 9 2009 480 490
42. C. Schindler, and C. Plumlee Inteferons pen the JAK-STAT pathway Semin. Cell Dev. Biol. 19 2008 311 318
43. T. Yin, M.L. Tsang, and Y.C. Yang JAK1 kinase forms complexes with interleukin-4 receptor and 4PS/insulin receptor substrate-1-like protein and is activated by interleukin-4 and interleukin-9 in T lymphocytes J. Biol. Chem. 269 1994 26614 26617 (Pubitemid 24332846)
44. B.A. Witthuhn, O. Silvennoinen, O. Miura, K.S. Lai, C. Cwik, and E.T. Liu Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells Nature 370 1994 153 157 (Pubitemid 24229129)
45. W. Wu, and X.H. Sun Janus kinase 3: the controller and the controlled Acta Biochim Biophys Sin (Shanghai) 44 2012 187 196
46. D. Watling, D. Guschin, M. Muller, O. Silvennoinen, B.A. Witthuhn, and F.W. Quelle Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway Nature 366 1993 166 170
47. M. Muller, J. Briscoe, C. Laxton, D. Guschin, A. Ziemiecki, and O. Silvennoinen The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction Nature 366 1993 129 135 (Pubitemid 23351817)
48. F.W. Quelle, N. Sato, B.A. Witthuhn, R.C. Inhorn, M. Eder, and A. Miyajima JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region Mol. Cell. Biol. 14 1994 4335 4341
49. A.L. Mui, H. Wakao, A.M. O'Farrell, N. Harada, and A. Miyajima Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs EMBO J. 14 1995 1166 1175
50. P. Igaz, S. Toth, and A. Falus Biological and clinical significance of the JAK-STAT pathway; lessons from knockout mice Inflamm. Res. 50 2001 435 441 (Pubitemid 32889442)
51. L.B. Ivashkiv, and X. Hu Signaling by STATs Arthritis Res. Ther. 6 2004 159 168 (Pubitemid 39162378)
52. H. Kiu, and S.E. Nicholson Biology and significance of the JAK/STAT signalling pathways Growth Factors 30 2012 88 106
53. S.J. Rodig, M.A. Meraz, J.M. White, P.A. Lampe, J.K. Riley, and C.D. Arthur Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the JAKs in cytokine-induced biologic responses Cell 93 1998 373 383 (Pubitemid 28232082)
54. H. Neubauer, A. Cumano, M. Muller, H. Wu, U. Huffstadt, and K. Pfeffer Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis Cell 93 1998 397 409 (Pubitemid 28232084)
55. K. Suzuki, H. Nakajima, Y. Saito, T. Saito, W.J. Leonard, and I. Iwamoto Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice Int. Immunol. 12 2000 123 132 (Pubitemid 30088304)
56. M. Karaghiosoff, H. Neubauer, C. Lassnig, P. Kovarik, H. Schindler, and H. Pircher Partial impairment of cytokine responses in Tyk2-deficient mice Immunity 13 2000 549 560
57. J.E. Durbin, R. Hackenmiller, M.C. Simon, and D.E. Levy Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease Cell 84 1996 443 450 (Pubitemid 26058569)
58. C. Park, S. Li, E. Cha, and C. Schindler Immune response in Stat2 knockout mice Immunity 13 2000 795 804 (Pubitemid 32041802)
59. W.E. Thierfelder, J.M. van Deursen, K. Yamamoto, R.A. Tripp, S.R. Sarawar, and R.T. Carson Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells Nature 382 1996 171 174 (Pubitemid 26242884)
60. K. Takeda, K. Noguchi, W. Shi, T. Tanaka, M. Matsumoto, and N. Yoshida Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality Proc. Natl. Acad. Sci. U. S. A. 94 1997 3801 3804 (Pubitemid 27180453)
61. S. Teglund, C. McKay, E. Schuetz, J.M. van Deursen, D. Stravopodis, and D. Wang Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses Cell 93 1998 841 850 (Pubitemid 28257589)
62. Y. Cui, G. Riedlinger, K. Miyoshi, W. Tang, C. Li, and C.X. Deng Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation Mol. Cell. Biol. 24 2004 8037 8047 (Pubitemid 39167454)
63. K. Takeda, M. Kamanaka, T. Tanaka, T. Kishimoto, and S. Akira Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice J. Immunol. 157 1996 3220 3222 (Pubitemid 126449129)
64. J.J. O'Shea, S.M. Holland, and Staudt L.M. JAKs STATs in immunity, immunodeficiency, and cancer N. Engl. J. Med. 368 2013 161 170
65. K. Shuai, and B. Liu Regulation of JAK-STAT signalling in the immune system Nat. Rev. Immunol. 3 2003 900 911 (Pubitemid 37411719)
66. J.C. Barrett, S. Hansoul, D.L. Nicolae, J.H. Cho, R.H. Duerr, and J.D. Rioux Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease Nat. Genet. 40 2008 955 962
67. A. Franke, T. Balschun, T.H. Karlsen, J. Hedderich, S. May, and T. Lu Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis Nat. Genet. 40 2008 713 715 (Pubitemid 351748866)
68. D.P. McGovern, A. Gardet, L. Torkvist, P. Goyette, J. Essers, and K.D. Taylor Genome-wide association identifies multiple ulcerative colitis susceptibility loci Nat. Genet. 42 2010 332 337
69. W. Strober, and I.J. Fuss Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases Gastroenterology 140 2011 1756 1767
70. M. Shale, C. Schiering, and F. Powrie CD4(+) T-cell subsets in intestinal inflammation Immunol. Rev. 252 2013 164 182
71. I.J. Fuss, M. Neurath, M. Boirivant, J.S. Klein, C. de la Motte, and S.A. Strong Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5 J. Immunol. 157 1996 1261 1270 (Pubitemid 126449643)
72. I.J. Fuss, F. Heller, M. Boirivant, F. Leon, M. Yoshida, and S. Fichtner-Feigl Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis J. Clin. Invest. 113 2004 1490 1497 (Pubitemid 39071705)
73. T. Korn, E. Bettelli, M. Oukka, and V.K. Kuchroo IL-17 and Th17 cells Annu. Rev. Immunol. 27 2009 485 517
74. S. Brand Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease Gut 58 2009 1152 1167
75. C.J. Beltran, L.E. Nunez, D. Diaz-Jimenez, N. Farfan, E. Candia, and C. Heine Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease Inflamm. Bowel Dis. 16 2010 1097 1107
76. K.M. Murphy, and S.L. Reiner The lineage decisions of helper T cells Nat. Rev. Immunol. 2 2002 933 944 (Pubitemid 37323214)
77. S. Brand, F. Beigel, T. Olszak, K. Zitzmann, S.T. Eichhorst, and J.M. Otte IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration Am J Physiol Gastrointest Liver Physiol 290 2006 G827 G838
78. S. Fujino, A. Andoh, S. Bamba, A. Ogawa, K. Hata, and Y. Araki Increased expression of interleukin 17 in inflammatory bowel disease Gut 52 2003 65 70 (Pubitemid 36020767)
79. F. Annunziato, L. Cosmi, V. Santarlasci, L. Maggi, F. Liotta, and B. Mazzinghi Phenotypic and functional features of human Th17 cells J. Exp. Med. 204 2007 1849 1861 (Pubitemid 47240944)
80. J. Seiderer, I. Elben, J. Diegelmann, J. Glas, J. Stallhofer, and C. Tillack Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD Inflamm. Bowel Dis. 14 2008 437 445 (Pubitemid 351571823)
81. J. Dambacher, F. Beigel, K. Zitzmann, E.N. De Toni, B. Goke, and H.M. Diepolder The role of the novel Th17 cytokine IL-26 in intestinal inflammation Gut 58 2009 1207 1217
82. L. Zhou, M.M. Chong, and D.R. Littman Plasticity of CD4+ T cell lineage differentiation Immunity 30 2009 646 655
83. M. Afkarian, J.R. Sedy, J. Yang, N.G. Jacobson, N. Cereb, and S.Y. Yang T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells Nat. Immunol. 3 2002 549 557 (Pubitemid 34662307)
84. S.J. Szabo, S.T. Kim, G.L. Costa, X. Zhang, C.G. Fathman, and L.H. Glimcher A novel transcription factor, T-bet, directs Th1 lineage commitment Cell 100 2000 655 669
85. J. Zhu, L. Guo, C.J. Watson, J. Hu-Li, and W.E. Paul Stat6 is necessary and sufficient for IL-4's role in Th2 differentiation and cell expansion J. Immunol. 166 2001 7276 7281 (Pubitemid 32525602)
86. W. Zheng, and R.A. Flavell The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells Cell 89 1997 587 596 (Pubitemid 27511769)
87. J. Zhu, J. Cote-Sierra, L. Guo, and W.E. Paul Stat5 activation plays a critical role in Th2 differentiation Immunity 19 2003 739 748 (Pubitemid 37490798)
88. W. Liao, D.E. Schones, J. Oh, Y. Cui, K. Cui, and T.Y. Roh Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression Nat. Immunol. 9 2008 1288 1296
89. I.I. Ivanov, B.S. McKenzie, L. Zhou, C.E. Tadokoro, A. Lepelley, and J.J. Lafaille The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells Cell 126 2006 1121 1133 (Pubitemid 44380299)
90. L. Durant, W.T. Watford, H.L. Ramos, A. Laurence, G. Vahedi, and L. Wei Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis Immunity 32 2010 605 615
91. J.J. O'Shea, R. Lahesmaa, G. Vahedi, A. Laurence, and Y. Kanno Genomic views of STAT function in CD4+ T helper cell differentiation Nat. Rev. Immunol. 11 2011 239 250
92. G.L. Stritesky, R. Muthukrishnan, S. Sehra, R. Goswami, D. Pham, and J. Travers The transcription factor STAT3 is required for T helper 2 cell development Immunity 34 2011 39 49
93. X.O. Yang, A.D. Panopoulos, R. Nurieva, S.H. Chang, D. Wang, and S.S. Watowich STAT3 regulates cytokine-mediated generation of inflammatory helper T cells J. Biol. Chem. 282 2007 9358 9363 (Pubitemid 47104613)
94. P. Miossec, and J.K. Kolls Targeting I.L-17 TH17 cells in chronic inflammation Nat. Rev. Drug Discov. 11 2012 763 776
95. M. Leppkes, C. Becker, I.I. Ivanov, S. Hirth, S. Wirtz, and C. Neufert RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F Gastroenterology 136 2009 257 267
96. W. O'Connor Jr., M. Kamanaka, C.J. Booth, T. Town, S. Nakae, and Y. Iwakura A protective function for interleukin 17A in T cell-mediated intestinal inflammation Nat. Immunol. 10 2009 603 609
97. X.O. Yang, S.H. Chang, H. Park, R. Nurieva, B. Shah, and L. Acero Regulation of inflammatory responses by IL-17F J. Exp. Med. 205 2008 1063 1075 (Pubitemid 351679682)
98. R. Ito, M. Kita, M. Shin-Ya, T. Kishida, A. Urano, and R. Takada Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice Biochem. Biophys. Res. Commun. 377 2008 12 16
99. A. Ogawa, A. Andoh, Y. Araki, T. Bamba, and Y. Fujiyama Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice Clin. Immunol. 110 2004 55 62 (Pubitemid 38177420)
100. J. Mudter, B. Weigmann, B. Bartsch, R. Kiesslich, D. Strand, and P.R. Galle Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases Am. J. Gastroenterol. 100 2005 64 72 (Pubitemid 41623270)
101. A. Musso, P. Dentelli, A. Carlino, L. Chiusa, A. Repici, and A. Sturm Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation Inflamm. Bowel Dis. 11 2005 91 98 (Pubitemid 40711212)
102. P. Lovato, C. Brender, J. Agnholt, J. Kelsen, K. Kaltoft, and A. Svejgaard Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease J. Biol. Chem. 278 2003 16777 16781 (Pubitemid 36799545)
103. S. Schreiber, P. Rosenstiel, J. Hampe, S. Nikolaus, B. Groessner, and A. Schottelius Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease Gut 51 2002 379 385
104. K. Sugimoto Role of STAT3 in inflammatory bowel disease World J. Gastroenterol. 14 2008 5110 5114
105. Y. Li, H.C. de, M.P. Peppelenbosch, and C.J. van der Woude New insights into the role of STAT3 in IBD Inflamm. Bowel Dis. 18 2012 1177 1183
106. A. Suzuki, T. Hanada, K. Mitsuyama, T. Yoshida, S. Kamizono, and T. Hoshino CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation J. Exp. Med. 193 2001 471 481 (Pubitemid 32524478)
107. K. Takeda, T. Kaisho, N. Yoshida, J. Takeda, T. Kishimoto, and S. Akira Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice J. Immunol. 161 1998 4652 4660 (Pubitemid 28492039)
108. R. Atreya, J. Mudter, S. Finotto, J. Mullberg, T. Jostock, and S. Wirtz Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo Nat. Med. 6 2000 583 588 (Pubitemid 30305911)
109. S.Z. Josefowicz, L.F. Lu, and A.Y. Rudensky Regulatory T cells: mechanisms of differentiation and function Annu. Rev. Immunol. 30 2012 531 564
110. S. Hori, T. Nomura, and S. Sakaguchi Control of regulatory T cell development by the transcription factor Foxp3 Science 299 2003 1057 1061 (Pubitemid 36222930)
111. Z. Yao, Y. Kanno, M. Kerenyi, G. Stephens, L. Durant, and W.T. Watford Nonredundant roles for Stat5a/b in directly regulating Foxp3 Blood 109 2007 4368 4375 (Pubitemid 46743405)
112. E. Bettelli, T. Korn, M. Oukka, and V.K. Kuchroo Induction and effector functions of T(H)17 cells Nature 453 2008 1051 1057 (Pubitemid 351871737)
113. J. Barbi, D. Pardoll, and F. Pan Metabolic control of the Treg/Th17 axis Immunol. Rev. 252 2013 52 77
114. M. Nishihara, H. Ogura, N. Ueda, M. Tsuruoka, C. Kitabayashi, and F. Tsuji IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state Int. Immunol. 19 2007 695 702 (Pubitemid 47078714)
115. A. Chaudhry, R.M. Samstein, P. Treuting, Y. Liang, M.C. Pils, and J.M. Heinrich Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation Immunity 34 2011 566 578
116. Y. Gu, J. Yang, X. Ouyang, W. Liu, H. Li, and J. Yang Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells Eur. J. Immunol. 38 2008 1807 1813
117. R. Kuhn, J. Lohler, D. Rennick, K. Rajewsky, and W. Muller Interleukin-10-deficient mice develop chronic enterocolitis Cell 75 1993 263 274 (Pubitemid 23320290)
118. S.D. Spencer, M.F. Di, J. Hooley, S. Pitts-Meek, M. Bauer, and A.M. Ryan The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor J. Exp. Med. 187 1998 571 578 (Pubitemid 28093359)
119. Y.P. Rubtsov, J.P. Rasmussen, E.Y. Chi, J. Fontenot, L. Castelli, and X. Ye Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces Immunity 28 2008 546 558
120. A. Chaudhry, D. Rudra, P. Treuting, R.M. Samstein, Y. Liang, and A. Kas CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner Science 326 2009 986 991
121. M. Murai, O. Turovskaya, G. Kim, R. Madan, C.L. Karp, and H. Cheroutre Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis Nat. Immunol. 10 2009 1178 1184
122. J. Bollrath, T.J. Phesse, V.A. von Burstin, T. Putoczki, M. Bennecke, and T. Bateman gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis Cancer Cell 15 2009 91 102
123. T.A. Willson, I. Jurickova, M. Collins, and L.A. Denson Deletion of intestinal epithelial cell STAT3 promotes T-lymphocyte STAT3 activation and chronic colitis following acute dextran sodium sulfate injury in mice Inflamm. Bowel Dis. 19 2013 512 525
124. T. Alonzi, I.P. Newton, P.J. Bryce, C.E. Di, G. Lattanzio, and M. Tripodi Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis Cytokine 26 2004 45 56 (Pubitemid 38410883)
125. K. Takeda, B.E. Clausen, T. Kaisho, T. Tsujimura, N. Terada, and I. Forster Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils Immunity 10 1999 39 49 (Pubitemid 29077382)
126. T. Welte, S.S. Zhang, T. Wang, Z. Zhang, D.G. Hesslein, and Z. Yin STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity Proc. Natl. Acad. Sci. U. S. A. 100 2003 1879 1884 (Pubitemid 36254542)
127. J.R. Goldsmith, J.M. Uronis, and C. Jobin Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signaling Am. J. Pathol. 179 2011 673 683
128. F. Tao, C. Qian, W. Guo, Q. Luo, Q. Xu, and Y. Sun Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin Biochem. Pharmacol. 85 2013 798 807
129. J.J. O'Shea, A. Kontzias, K. Yamaoka, Y. Tanaka, and A. Laurence Janus kinase inhibitors in autoimmune diseases Ann. Rheum. Dis. 72 Suppl 2 2013 ii111 ii115
130. P. Macchi, A. Villa, S. Giliani, M.G. Sacco, A. Frattini, and F. Porta Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) Nature 377 1995 65 68
131. S.M. Russell, N. Tayebi, H. Nakajima, M.C. Riedy, J.L. Roberts, and M.J. Aman Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development Science 270 1995 797 800
132. K. Ghoreschi, M.I. Jesson, X. Li, J.L. Lee, S. Ghosh, and J.W. Alsup Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550) J. Immunol. 186 2011 4234 4243
133. K. Migita, T. Miyashita, Y. Izumi, T. Koga, A. Komori, and Y. Maeda Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production BMC Immunol 12 2011 51
134. G.R. Lichtenstein, M.T. Abreu, R. Cohen, and W. Tremaine American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease Gastroenterology 130 2006 940 987 (Pubitemid 43374543)
135. W.J. Sandborn, S. Ghosh, J. Panes, I. Vranic, J. Spanton, and W. Niezychowski Phase 2 randomized study of CP-690,550, an oral Janus kinase inhibitor, in active Crohn's disease Gastroenterology 140 Suppl 2011 S124
136. H. Yoshida, A. Kimura, T. Fukaya, T. Sekiya, R. Morita, and T. Shichita Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation Biochem. Biophys. Res. Commun. 418 2012 234 240
137. R. Fleischmann, J. Kremer, J. Cush, H. Schulze-Koops, C.A. Connell, and J.D. Bradley Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis N. Engl. J. Med. 367 2012 495 507
138. R.F. van Vollenhoven, R. Fleischmann, S. Cohen, E.B. Lee, J.A. Garcia Meijide, and S. Wagner Tofacitinib or adalimumab versus placebo in rheumatoid arthritis N. Engl. J. Med. 367 2012 508 519
139. G.R. Burmester, R. Blanco, C. Charles-Schoeman, J. Wollenhaupt, C. Zerbini, and B. Benda Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Lancet 381 2013 451 460
140. N.K. Williams, R.S. Bamert, O. Patel, C. Wang, P.M. Walden, and A.F. Wilks Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains J. Mol. Biol. 387 2009 219 232
141. M.J. Pattison, K.F. Mackenzie, and J.S. Arthur Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback J. Immunol. 189 2012 2784 2792